Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patients.
Bouabdallah R, Stoppa AM, Rossi JF, Lepeu G, Coso D, Xerri L, Ladaique P, Chabannon C, Blaise D, Bardou VJ, Alzieu C, Gastaut JA, Maraninchi D. Bouabdallah R, et al. Among authors: bardou vj. Leukemia. 1999 Jun;13(6):950-6. doi: 10.1038/sj.leu.2401444. Leukemia. 1999. PMID: 10360385
Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
Costello RT, Zerazhi H, Charbonnier A, de Colella JM, Alzieu C, Poizot-Martin I, Cohen R, Bardou VJ, Xerri L, Olive D, Nezri M, Lepeu G, Gastaut JA. Costello RT, et al. Among authors: bardou vj. Cancer. 2004 Feb 15;100(4):667-76. doi: 10.1002/cncr.20019. Cancer. 2004. PMID: 14770420 Free article. Clinical Trial.
Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery.
Faucher C, Le Corroller AG, Chabannon C, Viens P, Stoppa AM, Bouabdallah R, Camerlo J, Vey N, Gravis G, Gastaut JA, Novakovitch G, Mannoni P, Bardou VJ, Moatti JP, Maraninchi D, Blaise D. Faucher C, et al. Among authors: bardou vj. J Hematother. 1996 Dec;5(6):663-70. doi: 10.1089/scd.1.1996.5.663. J Hematother. 1996. PMID: 9117255
Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: a report of six cases in a cohort of 171 patients from a single institution.
Oddou S, Vey N, Viens P, Bardou VJ, Faucher C, Stoppa AM, Chabannon C, Camerlo J, Bouabdallah R, Gastaut JA, Maraninchi D, Blaise D. Oddou S, et al. Among authors: bardou vj. Leuk Lymphoma. 1998 Sep;31(1-2):187-94. doi: 10.3109/10428199809057598. Leuk Lymphoma. 1998. PMID: 9720728 Clinical Trial.
Clinical outcome after front-line intensive sequential chemotherapy (ISC) in patients with aggressive non-Hodgkin's lymphoma and high-risk international prognostic index (IPI 3): final analysis of survival in two consecutive ISC trials.
Bouabdallah R, Stoppa AM, Coso D, Bardou VJ, Blaise D, Chabannon C, Gastaut JA, Maraninchi D. Bouabdallah R, et al. Among authors: bardou vj. Ann Oncol. 2001 Apr;12(4):513-7. doi: 10.1023/a:1011160207382. Ann Oncol. 2001. PMID: 11398886 Free article.
Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy.
Viret F, Chabannon C, Sainty D, Genre D, Gonçalves A, Arnoulet C, Gravis G, Bertucci F, Houvenaeghel G, Jacquemier J, Bardou VJ, Ladaique P, Braud AC, Maraninchi D, Viens P. Viret F, et al. Among authors: bardou vj. Bone Marrow Transplant. 2003 Dec;32(11):1059-64. doi: 10.1038/sj.bmt.1704283. Bone Marrow Transplant. 2003. PMID: 14625576 Clinical Trial.
68 results